Profile Image
Debra Hoppensteadt-Moorman Photo
Name
Debra Hoppensteadt-Moorman
Degree
Ph.D.
Rank
Professor
Primary Department
Pathology
Joint Department
Molecular Pharmacology and Neuroscience
Education
Advanced Degrees
University of London , London , FR , United Kingdom
Hobbies
Cooking
Keywords
Pharmacotherapy
Prenatal Factors
Thrombosis
Publications
Shih,L.; Guler,N.; Syed,D.; Hopkinson,W.; McComas,K. N.; Walborn,A.; Hoppensteadt,D.; Fareed,J.; Rondina,M. T.Postoperative Changes in the Systemic Inflammatory Milieu in Older Surgical Patients Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018 ;24(4):583-588
Otto,A.; Fareed,J.; Liles,J.; Statz,S.; Walborn,A.; Rowe,T.; Jabati,S.; Hoppensteadt,D.; Syed,M. A.Fibrinolytic Deficit and Platelet Activation in Atrial Fibrillation and Their Postablation Modulation Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018 ; :1076029617750270
Edberg,D.; Hoppensteadt,D.; Walborn,A.; Fareed,J.; Sinacore,J.; Halaris,A.Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment Journal of psychiatric research 2018 ;102:1-7
Jabati,S.; Fareed,J.; Liles,J.; Otto,A.; Hoppensteadt,D.; Bontekoe,J.; Phan,T.; Walborn,A.; Syed,M.Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018 ; :1076029618761006
McClane,N.; Jeske,W.; Walenga,J. M.; Escalante,V.; Hoppensteadt,D.; Schwartz,J.; Bakhos,M.Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018 ; :1076029618760235
McMillan,R.; Skiadopoulos,L.; Hoppensteadt,D.; Guler,N.; Bansal,V.; Parasuraman,R.; Fareed,J.Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2018 ;24(2):235-240
McMillan,R.; Skiadopoulos,L.; Hoppensteadt,D.; Guler,N.; Bansal,V.; Parasuraman,R.; Fareed,J.Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2017 ; :1076029617729216
Saluk,J.; Hoppensteadt,D.; Syed,D.; Liles,J.; Abro,S.; Walborn,A.; Bansal,V.; Fareed,J.Biomarker profiling of plasma samples for various diseases utilizing RANDOX Biochip Array Technology International angiology : a journal of the International Union of Angiology 2017 ; :
Liu,X.; St Ange,K.; Fareed,J.; Hoppensteadt,D.; Jeske,W.; Kouta,A.; Chi,L.; Jin,C.; Jin,Y.; Yao,Y.; Linhardt,R. J.Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2017 ; :1076029616686422
Xu,Y.; Chandarajoti,K.; Zhang,X.; Pagadala,V.; Dou,W.; Hoppensteadt,D. M.; Sparkenbaugh,E. M.; Cooley,B.; Daily,S.; Key,N. S.; Severynse-Stevens,D.; Fareed,J.; Linhardt,R. J.; Pawlinski,R.; Liu,J.Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins Science translational medicine 2017 ;9(406):10.1126/scitranslmed.aan5954
Walborn,A.; Hoppensteadt,D.; Syed,D.; Mosier,M.; Fareed,J.Biomarker Profile of Sepsis-Associated Coagulopathy Using Biochip Assay for Inflammatory Cytokines Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2017 ; :1076029617709084
Wanderling,C.; Liles,J.; Davis,E.; Schmitt,D.; Statz,S.; Guler,N.; Hoppensteadt,D.; Fareed,J.; Hopkinson,W.Levels of Matrix-Degrading Enzymes and Lubricin in Patients With Degenerative Joint Disease Requiring Arthroplasty Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2017 ; :1076029617724231
Wanderling,C.; Liles,J.; Finkler,E.; Carlsgaard,P.; Hopkinson,W.; Guler,N.; Hoppensteadt,D.; Fareed,J.Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2017 ; :1076029617700998
Sweigert,P. J.; Bansal,V. K.; Hoppensteadt,D. A.; Saluk,J. L.; Syed,D. A.; Fareed,J.Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease The International journal of angiology : official publication of the International College of Angiology, Inc 2017 ;26(1):43-48
Clark-Raymond,A.; Meresh,E.; Hoppensteadt,D.; Fareed,J.; Sinacore,J.; Garlenski,B.; Halaris,A.Vascular endothelial growth factor: Potential predictor of treatment response in major depression The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2016 ; :1-11
Sadeghi,N.; Iacobelli,M.; Vaziri,B.; Kahn,D.; Hoppensteadt,D.; Guler,N.; Fareed,J.Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates: Studies on the Comparison of NovoSeven With a Biosimilar Product Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 ; :
Saluk,J. L.; Banos,A. L.; Hopkinson,W. L.; Rees,H. L.; Syed,D.; Hoppensteadt,D.; Abro,S.; Iqbal,O.; Fareed,J.Prevalence of metabolic syndrome in patients undergoing total joint arthroplasty and relevance of biomarkers International angiology : a journal of the International Union of Angiology 2016 ; :
Saluk,J. L.; Bansal,V.; Hoppensteadt,D.; Syed,D.; Abro,S.; Fareed,J.Effect of erythropoietin stimulating agents on vascular endothelial growth factor levels in patients with end stage renal disease International angiology : a journal of the International Union of Angiology 2016 ; :
Dansdill,D.; Halandras,P. M.; Beverly,J.; Jeske,W.; Hoppensteadt,D.; Emanuele,M.; Fareed,J.; Cho,J. S.Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator Journal of Vascular Surgery 2016 ; :
Alexander,K.; Banos,A.; Abro,S.; Hoppensteadt,D.; Fareed,J.; Rees,H.; Hopkinson,W.Levels of Matrix Metalloproteinases in Arthroplasty Patients and Their Correlation With Inflammatory and Thrombotic Activation Processes Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 ; :
Burleson,A.; Guler,N.; Banos,A.; Syed,D.; Wanderling,C.; Hoppensteadt,D.; Rees,H.; Fareed,J.; Hopkinson,W.Perioperative Factors and Their Effect on the Fibrinolytic System in Arthroplasty Patients Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 ;22(3):274-279
Lattimer,C. R.; Kalodiki,E.; Geroulakos,G.; Hoppensteadt,D.; Fareed,J.Are Inflammatory Biomarkers Increased in Varicose Vein Blood? Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 ; :
Low,C.; Syed,D.; Khan,D.; Tetik,S.; Walborn,A.; Hoppensteadt,D.; Mosier,M.; Fareed,J.Modulation of Interleukins in Sepsis-Associated Clotting Disorders: Interplay With Hemostatic Derangement Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 ; :
Guler,N.; Abro,S.; Emanuele,M.; Iqbal,O.; Hoppensteadt,D.; Fareed,J.The Protective Effect of Poloxamer-188 on Platelet Functions Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 ; :
St Ange,K.; Onishi,A.; Fu,L.; Sun,X.; Lin,L.; Mori,D.; Zhang,F.; Dordick,J. S.; Fareed,J.; Hoppensteadt,D.; Jeske,W.; Linhardt,R. J.Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 ; :
Abro,S.; Clark,M.; Barkan,G.; Hoppensteadt,D.; Fareed,J.; Wojick,E.; Quek,M.Inflammation and Hemostatic Activation may Contribute to Postsurgical Thrombosis in Patients With Bladder Cancer Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 ;22(4):314-321
Liles,J.; Liles,J.; Wanderling,C.; Syed,M.; Hoppensteadt,D.; Fareed,J.Increased Level of Thrombotic Biomarkers in Patients with Atrial Fibrillation Despite Traditional and New Anticoagulant Therapy Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2016 ; :
Guler,N.; Burleson,A.; Syed,D.; Banos,A.; Hopkinson,W.; Hoppensteadt,D.; Rees,H.; Fareed,J.Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients: Potential Clinical Implications Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2015 ; :
Lattimer,C. R.; Kalodiki,E.; Geroulakos,G.; Hoppensteadt,D.; Fareed,J.Endogenous pro-thrombotic biomarkers from the arm and leg may not have the same value Phlebology / Venous Forum of the Royal Society of Medicine 2015 ; :
Lattimer,C. R.; Kalodiki,E.; Geroulakos,G.; Syed,D.; Hoppensteadt,D.; Fareed,J.d-Dimer Levels are Significantly Increased in Blood Taken From Varicose Veins Compared With Antecubital Blood From the Same Patient Angiology 2015 ;66(9):882-888
Richards,J.; Bansal,V.; Iqbal,O.; Hoppensteadt,D.; Fareed,J.Immunoenzymatic and Biochip Array Profiling of the Biomarkers of Inflammation and Hemostatic Activation Processes in ESRD Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2015 ;21(5):405-11
Kalodiki,E.; Fareed,J.; Syed,D.; Geroulakos,G.; Hoppensteadt,D.; Lattimer,C. R.Blood Sampled Directly from Varicose Veins Reveals Activation of Inflammatory Processes Journal of vascular surgery.Venous and lymphatic disorders 2015 ;3(1):119
Halaris,A.; Myint,A. M.; Savant,V.; Meresh,E.; Lim,E.; Guillemin,G.; Hoppensteadt,D.; Fareed,J.; Sinacore,J.Does escitalopram reduce neurotoxicity in major depression? Journal of psychiatric research 2015 ;66-67:118-126
Syed,D.; Iqbal,O.; Mosier,M.; Mitchell,R.; Hoppensteadt,D.; Bouchard,C.; Fareed,J.; Gamelli,R.Elevated endocan levels and its association with clinical severity in Stevens-Johnson Syndrome and toxic epidermal necrolysis International angiology : a journal of the International Union of Angiology 2015 ;34(5):483-488
Clark-Raymond,A.; Meresh,E.; Hoppensteadt,D.; Fareed,J.; Sinacore,J.; Halaris,A.Vascular Endothelial Growth Factor: a potential diagnostic biomarker for major depression Journal of psychiatric research 2014 ;59:22-27
Saluk,J.; Bansal,V.; Hoppensteadt,D.; Syed,D.; Abro,S.; Fareed,J.Prevalence of metabolic syndrome in patients with end stage renal disease and relevance of biomarkers International angiology : a journal of the International Union of Angiology 2014 ; :
Hoppensteadt,D.; Tsuruta,K.; Cunanan,J.; Hirman,J.; Kaul,I.; Osawa,Y.; Fareed,J.Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2014 ;20(2):129-135
Hoppensteadt,D. A.; Fareed,J.Pharmacological profile of sulodexide International angiology : a journal of the International Union of Angiology 2014 ;33(3):229-235
Hoppensteadt,D. A.; Gray,A.; Jeske,W. P.; Walenga,J. M.; Fareed,J.Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2014 ;20(6):621-628
Dibble,S.; Andersen,A.; Lassen,M. R.; Cunanan,J.; Hoppensteadt,D.; Fareed,J.Inflammatory and procoagulant cytokine levels during pregnancy as predictors of adverse obstetrical complications Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2014 ;20(2):152-158
Saban,K. L.; Hoppensteadt,D.; Bryant,F. B.; DeVon,H. A.Social determinants and heat shock protein-70 among African American and non-Hispanic white women with atherosclerosis: a pilot study Biological research for nursing 2014 ;16(3):258-265
Sadeghi,N.; Kahn,D.; Syed,D.; Iqbal,O.; Abro,S.; Eshraghi,R.; Hoppensteadt,D.; Fareed,J.Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2014 ;20(6):565-572
Walenga,J. M.; Kaiser,P. C.; Prechel,M. M.; Hoppensteadt,D.; Jeske,W. P.; Misselwitz,F.; Bacher,P.; Lassen,M. R.; Fareed,J.Sustained release of tissue factor following thrombosis of lower limb trauma Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2014 ;20(7):678-686
Walenga,J. M.; Jeske,W. P.; Hoppensteadt,D.; Cunanan,J.; Khan,H.; Escalante,V.; Fareed,J.; Bakhos,M.Comparative studies on branded enoxaparin and a US generic version of enoxaparin Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2013 ;19(3):261-267
Sadeghi,N.; Kahn,D.; Jeske,W.; Hoppensteadt,D.; Fareed,J.Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2013 ;19(6):589-599
Sharain,K.; Hoppensteadt,D.; Bansal,V.; Singh,A.; Fareed,J.Progressive increase of inflammatory biomarkers in chronic kidney disease and end-stage renal disease Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2013 ;19(3):303-308
Kaneva,K.; Bansal,V.; Hoppensteadt,D.; Cunanan,J.; Fareed,J.Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2013 ;19(4):449-452
Govindan,S.; Kuster,D. W.; Lin,B.; Kahn,D. J.; Jeske,W. P.; Walenga,J. M.; Leya,F.; Hoppensteadt,D.; Fareed,J.; Sadayappan,S.Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction American journal of cardiovascular disease 2013 ;3(2):60-70
Walenga,J. M.; Prechel,M.; Hoppensteadt,D.; Escalante,V.; Chaudhry,T.; Jeske,W. P.; Bakhos,M.Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2013 ;19(5):482-487
Kowal-Vern,A.; Walenga,J. M.; Hoppensteadt,D.; Gamelli,R. L.Prothrombin fragment 1.2 and modified antithrombin as predictors of disseminated intravascular coagulation and thrombotic risk in thermal injury Journal of burn care & research : official publication of the American Burn Association 2013 ;34(4):459-464
Walenga,J. M.; Jeske,W. P.; Escalante,V.; Hoppensteadt,D.; Fareed,J.; Bakhos,M.Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins International angiology : a journal of the International Union of Angiology 2012 ;31(6):517-525
Gray,A.; Litinas,E.; Jeske,W.; Fareed,J.; Hoppensteadt,D.Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin. Clinical & Applied Thrombosis/Hemostasis 2012 ;18(2):166-173
Jeske,W.; Litinas,E.; Khan,H.; Hoppensteadt,D.; Fareed,J.A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates. Clinical & Applied Thrombosis/Hemostasis 2012 ;18(3):294-298
Sadeghi,N.; Zhu,H.; Setty,S. K.; Cunanan,J.; Hoppensteadt,D.; Fareed,J.Cross-reactivity of various thrombin products with anti-rabbit antibodies to bovine, human, and recombinant thrombin. Clinical & Applied Thrombosis/Hemostasis 2012 ;18(3):243-248
Fareed,J.; Thethi,I.; Hoppensteadt,D.Old versus new oral anticoagulants: focus on pharmacology Annual Review of Pharmacology & Toxicology 2012 ;52:79-99
Nelson,K.; Thethi,I.; Cunanan,J.; Hoppensteadt,D.; Bajwa,R.; Fareed,J.; Bansal,V.Upregulation of surrogate markers of inflammation and thrombogenesis in patients with ESRD: pathophysiologic and therapeutic implications. Clinical & Applied Thrombosis/Hemostasis 2011 ;17(3):302-304
Jeske,W. P.; Hoppensteadt,D.; Gray,A.; Walenga,J. M.; Cunanan,J.; Myers,L.; Fareed,J.; Bayol,A.; Rigal,H.; Viskov,C.A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Thrombosis research 2011 ;128(4):361-367
Jeske,W. P.; Walenga,J. M.; Samama,M. M.; Hoppensteadt,D.; Mayuga,M.; Fareed,J.Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Blood Coagulation & Fibrinolysis 2011 ;22(3):206-210
Ramacciotti,E.; Clark,M.; Sadeghi,N.; Hoppensteadt,D.; Thethi,I.; Gomes,M.; Fareed,J.Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications Clinical & Applied Thrombosis/Hemostasis 2011 ;17(2):126-135
Gomes,M.; Ramacciotti,E.; Hoppensteadt,D.; Walenga,J. M.; Lewis,B.; Thethi,I.; Fareed,J.An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers. Clinical & Applied Thrombosis/Hemostasis 2011 ;17(1):66-69
Genzen,J. R.; Fareed,J.; Hoppensteadt,D.; Kurup,V.; Barash,P.; Coady,M.; Wu,Y. Y.Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. Transfusion 2010 ;50(4):801-807
Knesek,M. J.; Litinas,E.; Adiguzel,C.; Hopkinson,W.; Hoppensteadt,D.; Lassen,M.; Fareed,J.Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins. Clinical & Applied Thrombosis/Hemostasis 2010 ;16(1):42-50
Kalodiki,E.; Fareed,J.; Tapson,W. F.; Hoppensteadt,D. A.; Carter,C. A.; Sussman,I.; Parker,S.; Harenberg,J.; Hull,R.; Rao,G.; Lovinger,D. F.; Reid,L. D.; Kakkar,A.; Talarico,L.; Ofosu,F. A.; Bussey,H. I.; Fanikos,J.; Groce,J. B.; Skinner,N.; Ahluwalia,M.; Iqbal,O.; Jackson,C. M.; Jeske,W. P.; Ramacciotti,E.; Van Thiel,D.; Wahi,R.; Walenga,J.A consensus conference on complex biologics and low molecular weight heparin International Angiology 2010 ;29(2):193
Erez,O.; Romero,R.; Vaisbuch,E.; Kusanovic,J. P.; Mazaki-Tovi,S.; Chaiworapongsa,T.; Gotsch,F.; Fareed,J.; Hoppensteadt,D.; Gabor,T. N.; Yoon,B. H.; Edwin,S.; Dong,Z.; Espinoza,J.; Mazor,M.; Hassan,S. S.High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor. Journal of Maternal-Fetal & Neonatal Medicine 2010 ;23(1):23-33
Fareed,J.; Hoppensteadt,D. A.; Ramacciotti,E.; Hull,R. D.Contaminants in heparins: are all facts known? Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2010 ;16(3):242-243
Hoppensteadt,D. A.; Neville,B.; Schultz,C.; Jeske,W.; Raake,W.; Fareed,J.Comparative studies on the topical administration of mucopolysaccharide and heparin ointments in nonhuman primates. Clinical & Applied Thrombosis/Hemostasis 2010 ;16(1):13-20
He,Z.; Hoppensteadt,D.; Cunanan,J.; Fareed,J.Cross-reactivity of rabbit anti-bovine thrombin IgGs with human alpha-thrombin and a recombinant version of human thrombin (Recothrom) Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2010 ;16(3):273-280
He,Z.; Hoppensteadt,D.; Morris,M.; Fareed,J.Cross-reactivity of rabbit anti-bovine prothrombin/thrombin IgGs with bovine factor V/Va-related antigens. Clinical & Applied Thrombosis/Hemostasis 2010 ;16(5):522-528
Kuziej,J.; Litinas,E.; Hoppensteadt,D. A.; Liu,D.; Walenga,J. M.; Fareed,J.; Jeske,W.In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2010 ;16(4):377-386
Panayiotou,A. G.; Nicolaides,A. N.; Griffin,M.; Tyllis,T.; Georgiou,N.; Bond,D.; Martin,R. M.; Hoppensteadt,D.; Fareed,J.; Humphries,S. E.Leukocyte telomere length is associated with measures of subclinical atherosclerosis. Atherosclerosis 2010 ;211(1):176-181
Piletz,J. E.; Halaris,A.; Iqbal,O.; Hoppensteadt,D.; Fareed,J.; Zhu,H.; Sinacore,J.; DeVane,C. L.P-selectin in major depression: preliminary findings with venlafaxine treatment International Journal of Health Science 2010 ;3(2):312-318
Piletz,J. E.; Halaris,A.; Iqbal,O.; Hoppensteadt,D.; Fareed,J.; Zhu,H.; Sinacore,J.; DeVane,C. L.Nitric oxide branch of arginine metabolism in depression: effect of venlafaxine International Journal of Health Science 2009 ;2(4):274-281
Piletz,J. E.; Halaris,A.; Iqbal,O.; Hoppensteadt,D.; Fareed,J.; Zhu,H.; Sinacore,J.; Devane,C. L.Pro-inflammatory biomakers in depression: treatment with venlafaxine. World Journal of Biological Psychiatry 2009 ;10(4):313-323
Adiguzel,C.; Bansal,V.; Litinas,E.; Cunanan,J.; Iqbal,O.; Nelson,K.; Kannan,M.; Hoppensteadt,D.; Fareed,J.Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Clinical & Applied Thrombosis/Hemostasis 2009 ;15(2):145-151
Adiguzel,C.; Iqbal,O.; Hoppensteadt,D.; Jeske,W.; Cunanan,J.; Litinas,E.; He,Z.; Walenga,J. M.; Fareed,J.Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Clinical & Applied Thrombosis/Hemostasis 2009 ;15(5):501-511
Adiguzel,C.; Jeske,W. P.; Hoppensteadt,D.; Walenga,J. M.; Bansal,V.; Fareed,J.Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Clinical & Applied Thrombosis/Hemostasis 2009 ;15(2):137-144
Zhu,H.; Hoppensteadt,D.; Adiguzel,C.; Bick,R. L.; Fareed,J.Comparison of immunogenic potentials of bovine thrombin preparations. Clinical & Applied Thrombosis/Hemostasis 2009 ;15(1):41-49
Zhu,H.; Hoppensteadt,D.; Iqbal,O.; Litinas,E.; Adiguzel,C.; Fareed,J.Relative purity of different bovine thrombin preparations. Clinical & Applied Thrombosis/Hemostasis 2009 ;15(6):681-688
Zhu,H.; Hoppensteadt,D.; Wahi,R.; Cunanan,J.; Adiguzel,C.; Bick,R. L.; Fareed,J.Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application. Clinical & Applied Thrombosis/Hemostasis 2009 ;15(1):32-40
Erez,O.; Gotsch,F.; Mazaki-Tovi,S.; Vaisbuch,E.; Kusanovic,J. P.; Kim,C. J.; Chaiworapongsa,T.; Hoppensteadt,D.; Fareed,J.; Than,N. G.; Nhan-Chang,C. L.; Yeo,L.; Pacora,P.; Mazor,M.; Hassan,S. S.; Mittal,P.; Romero,R.Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. Journal of Maternal-Fetal & Neonatal Medicine 2009 ;22(8):672-687
Li,B.; Suwan,J.; Martin,J. G.; Zhang,F.; Zhang,Z.; Hoppensteadt,D.; Clark,M.; Fareed,J.; Linhardt,R. J.Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochemical pharmacology 2009 ;78(3):292-300
Viskov,C.; Bouley,E.; Hubert,P.; Martinez,C.; Herman,F.; Jeske,W.; Hoppensteadt,D.; Walenga,J. M.; Fareed,J.Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin. Clinical & Applied Thrombosis/Hemostasis 2009 ;15(4):395-401
Walenga,J. M.; Drenth,A. F.; Mayuga,M.; Hoppensteadt,D. A.; Prechel,M.; Harder,S.; Watanabe,H.; Osakabe,M.; Breddin,H. K.Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Clinical & Applied Thrombosis/Hemostasis 2008 ;14(3):325-331
Walenga,J. M.; Prechel,M.; Jeske,W. P.; Hoppensteadt,D.; Maddineni,J.; Iqbal,O.; Messmore,H. L.; Bakhos,M.Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. British journal of haematology 2008 ;143(1):92-99
Jeske,W. P.; Walenga,J. M.; Hoppensteadt,D. A.; Vandenberg,C.; Brubaker,A.; Adiguzel,C.; Bakhos,M.; Fareed,J.Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins Seminars in Thrombosis & Hemostasis 2008 ;34(1):74-85
Nien,J. K.; Romero,R.; Hoppensteadt,D.; Erez,O.; Espinoza,J.; Soto,E.; Kusanovic,J. P.; Gotsch,F.; Kim,C. J.; Mittal,P.; Fareed,J.; Santolaya,J.; Chaiworapongsa,T.; Edwin,S.; Pineles,B.; Hassan,S.Pyelonephritis during pregnancy: a cause for an acquired deficiency of protein Z. Journal of Maternal-Fetal & Neonatal Medicine 2008 ;21(9):629-637
Hoppensteadt,D.; Fareed,J.; Klein,A. L.; Jasper,S. E.; Apperson-Hansen,C.; Lieber,E. A.; Katz,W. E.; Malouf,J. F.; Stoddard,M. F.; Pape,L. A.Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. American Journal of Cardiology 2008 ;102(7):842-846
Hoppensteadt,D. A.; Fabbrini,N.; Bick,R. L.; Messmore,H. L.; Adiguzel,C.; Fareed,J.Laboratory evaluation of the antiphospholipid syndrome Hematology - Oncology Clinics of North America 2008 ;22(1):19-32
Hoppensteadt,D. A.; Jeske,W.; Walenga,J. M.; Bick,R. L.; Fareed,J.The anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors: experimental and clinical observations. Seminars in Thrombosis and Hemostasis 2008 ;34(Suppl 1):97-102
Hoppensteadt,D. A.; Jeske,W.; Walenga,J. M.; Fareed,J.The future of anticoagulation Seminars in Respiratory & Critical Care Medicine 2008 ;29(1):90-99
Hoppensteadt,D. A.; Wahi,R.; Adiguzel,C.; Iqbal,O.; Ramacciotti,E.; Bick,R. L.; Messmore,H. L.; Bansal,V.; Fareed,J.Contaminant in the recalled unfractionated heparin preparations: where is the problem?. Clinical & Applied Thrombosis/Hemostasis 2008 ;14(3):261-266
Hoppensteadt,D. A.; Walenga,J. M.The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia Hematology - Oncology Clinics of North America 2008 ;22(1):1-18
Clark,M.; Hoppensteadt,D.; Walenga,J. M.; Myers,L.; Cunanan,J.; Jeske,W.; Adiguzel,C.; Iqbal,O.; Fareed,J.Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. International Angiology 2008 ;27(5):370-376
Adiguzel,C.; Iqbal,O.; Cunanan,J.; Jeske,W.; Hoppensteadt,D.; Walenga,J. M.; Fareed,J.Potency Adjusted Generic Versions of Argatroban can be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays Seminars in Thrombosis and Hemostasis 2008 ;34:108
Erez,O.; Espinoza,J.; Chaiworapongsa,T.; Gotsch,F.; Kusanovic,J. P.; Than,N. G.; Mazaki-Tovi,S.; Vaisbuch,E.; Papp,Z.; Yoon,B. H.; Han,Y. M.; Hoppensteadt,D.; Fareed,J.; Hassan,S. S.; Romero,R.A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor. Journal of Maternal-Fetal & Neonatal Medicine 2008 ;21(10):732-744
Erez,O.; Romero,R.; Hoppensteadt,D.; Fareed,J.; Chaiworapongsa,T.; Kusanovic,J. P.; Mazaki-Tovi,S.; Gotsch,F.; Than,N. G.; Vaisbuch,E.; Kim,C. J.; Espinoza,J.; Mittal,P.; Hamill,N.; Nhan-Chang,C. L.; Mazor,M.; Hassan,S.Premature labor: a state of platelet activation?. Journal of perinatal medicine 2008 ;36(5):377-387
Fareed,J.; Ahluwalia,M.; Wahi,R.; Ramaccioti,E.; Hoppensteadt,D.; Bick,R. L.Contaminants in heparins continue to be unfolded. International Angiology 2008 ;27(6):457-461
Fareed,J.; Hoppensteadt,D. A.; Fareed,D.; Demir,M.; Wahi,R.; Clarke,M.; Adiguzel,C.; Bick,R.Survival of heparins, oral anticoagulants, and aspirin after the year 2010 Seminars in Thrombosis & Hemostasis 2008 ;34(1):58-73
Fareed,J.; Jeske,W.; Fareed,D.; Clark,M.; Wahi,R.; Adiguzel,C.; Hoppensteadt,D.Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Clinical & Applied Thrombosis/Hemostasis 2008 ;14(4):385-392
Fareed,J.; Walenga,J. M.; Hoppensteadt,D. A.; Bick,R. L.; Messmore,H. L.Dr. Eberhard F. Mammen remembered. A great clinician-scientist, mentor, and friend. Seminars in Thrombosis and Hemostasis 2008 ;34(Suppl 1):128-129
Fareed,J.; Walenga,J. M.; Jeske,W. P.; Hoppensteadt,D.; Prechel,M.; Iqbal,O.; Adiguzel,C.; Clark,M.; Litinas,E.; cunanan,J.; Linhardt,R.; Harenberg,J.Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin Seminars in thrombosis and hemostatis 2008 ;34(supplement 1):119-127
Jeske,W. P.; McDonald,M. K.; Hoppensteadt,D. A.; Bau,E. C.; Mendes,A.; Dietrich,C. P.; Walenga,J. M.; Coyne,E.Isolation and characterization of heparin from tuna skins. Clinical & Applied Thrombosis/Hemostasis 2007 ;13(2):137-145
Maddineni,J.; Hoppensteadt,D. A.; Cornelli,U.; Manoni,M.; Fareed,J.Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate. Clinical & Applied Thrombosis/Hemostasis 2007 ;13(1):52-64
Ravindranath,T. M.; Goto,M.; Iqbal,O.; Florian-Kujawski,M.; Hoppensteadt,D.; Hammadeh,R.; Sayeed,M. M.; Fareed,J.Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clinical & Applied Thrombosis/Hemostasis 2007 ;13(4):362-368
Ma,Q.; Tobu,M.; Schultz,C.; Jeske,W.; Hoppensteadt,D. A.; Walenga,J. M.; Cornelli,U.; Lee,J.; Linhardt,R.; Hanin,I.; Fareed,J.Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thrombosis research 2007 ;119(5):653-661
Fareed,J.; Jeske,W. P.; Hoppensteadt,D. A.; Walenga,J. M.Update on the clinical applications of argatroban. Future Cardiology 2006 ;2(4):403-414
Maddineni,J.; Jeske,W. P.; Baltasar,F.; Cornelli,U.; Manoni,M.; Hoppensteadt,D. A.; Fareed,J.Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis. Clinical & Applied Thrombosis/Hemostasis 2006 ;12(3):311-317
Maddineni,J.; Walenga,J. M.; Jeske,W. P.; Hoppensteadt,D. A.; Fareed,J.; Wahi,R.; Bick,R. L.Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications Clinical & Applied Thrombosis/Hemostasis 2006 ;12(3):267-276
Iqbal,O.; Tobu,M.; Aziz,S.; Gerdisch,M.; Da Valle,M.; Demir,M.; Hoppensteadt,D. A.; Ahmad,S.; Walenga,J. M.; Fareed,J.Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. Journal of cardiac surgery 2005 ;20(1):42-51
Tobu,M.; Ma,Q.; Iqbal,O.; Schultz,C.; Jeske,W.; Hoppensteadt,D. A.; Fareed,J.Comparative tissue factor pathway inhibitor release potential of heparins. Clinical & Applied Thrombosis/Hemostasis 2005 ;11(1):37-47
Fareed,J.; Leong,W.; Hoppensteadt,D. A.; Jeske,W. P.; Walenga,J. M.; Bick,R. L.Development of generic low molecular weight heparins: a perspective Hematology - Oncology Clinics of North America 2005 ;19(1):53-68
Fareed,J.; Leong,W. L.; Hoppensteadt,D. A.; Jeske,W. P.; Walenga,J. M.; Wahi,R.; Bick,R. L.Generic low-molecular-weight heparins: some practical considerations Seminars in Thrombosis & Hemostasis 2004 ;30(6):703-713
Fareed,J.; Ma,Q.; Florian,M.; Maddineni,J.; Iqbal,O.; Hoppensteadt,D. A.; Bick,R. L.Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis Seminars in Thrombosis & Hemostasis 2004 ;30(Suppl 1):89-104
Walenga,J. M.; Hoppensteadt,D. A.Monitoring the new antithrombotic drugs.[erratum appears in Semin Thromb Hemost. 2005 Apr;31(2):247] Seminars in Thrombosis & Hemostasis 2004 ;30(6):683-695
Walenga,J. M.; Jeske,W. P.; Hoppensteadt,D.; Fareed,J.Factor Xa inhibitors Methods in Molecular Medicine 2004 ;93:95-117
Florian-Kujawski,M.; Hoppensteadt,D.; Maddineni,J.; Ziegler,H.; Fareed,J.Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications. International Angiology 2004 ;23(4):346-354
Florian-Kujawski,M.; Hussain,W.; Chyna,B.; Kahn,S.; Hoppensteadt,D.; Leya,F.; Fareed,J.Biomarker profiling of plasma from acute coronary syndrome patients. Application of ProteinChip Array analysis. International Angiology 2004 ;23(3):246-254
Maddineni,J.; Ma,Q.; Hoppensteadt,D. A.; Demir,M.; Manoni,M.; Cornelli,U.; Fareed,J.Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan. Clinical & Applied Thrombosis/Hemostasis 2004 ;10(1):27-37
Ahmad,S.; Untch,B.; Haas,S.; Hoppensteadt,D. A.; Misselwitz,F.; Messmore,H. L.; Walenga,J. M.; Fareed,J.Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis. Molecular & Cellular Biochemistry 2004 ;258(1-2):163-170
Fareed,D.; Iqbal,O.; Tobu,M.; Hoppensteadt,D. A.; Fareed,J.Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications. Clinical & Applied Thrombosis/Hemostasis 2004 ;10(4):357-364
Fareed,J.; Hoppensteadt,D.; Schultz,C.; Ma,Q.; Kujawski,M. F.; Neville,B.; Messmore,H.Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile Current pharmaceutical design 2004 ;10(9):983-999
Tobu,M.; Iqbal,O.; Fareed,D.; Chatha,M.; Hoppensteadt,D.; Bansal,V.; Fareed,J.Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clinical & Applied Thrombosis/Hemostasis 2004 ;10(3):225-232
Tobu,M.; Iqbal,O.; Hoppensteadt,D.; Neville,B.; Messmore,H. L.; Fareed,J.Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clinical & Applied Thrombosis/Hemostasis 2004 ;10(4):301-309
Hoppensteadt,D. A.; Fareed,J.; Bick,R. L.Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology. Seminars in Thrombosis & Hemostasis 2004 ;30(Suppl 1):105-108
Hoppensteadt,D. A.; Willows,L.; Leitz,H.; Nicolaides,A.; Fareed,J.Laboratory analysis of blood samples from patients treated with tinzaparin. Seminars in Thrombosis & Hemostasis 2004 ;30(Suppl 1):49-55
Fareed,J.; Hoppensteadt,D.; Walenga,J. M.; Iqbal,O.; Ma,Q.; Jeske,W.; Sheikh,T.Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice Clinical pharmacokinetics 2003 ;42(12):1043-1057
Fareed,J.; Hoppensteadt,D. A.; Bick,R. L.Management of thrombotic and cardiovascular disorders in the new millenium Clinical & Applied Thrombosis/Hemostasis 2003 ;9(2):101-108
Walenga,J. M.; Jeske,W. P.; Hoppensteadt,D.; Fareed,J.Factor Xa inhibitors: today and beyond Current Opinion in Investigational Drugs 2003 ;4(3):272-281
Tobu,M.; Iqbal,O.; Ma,Q.; Schultz,C.; Jeske,W.; Hoppensteadt,D.; Lewis,B.; Fareed,D.; Fareed,J.Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use. Clinical & Applied Thrombosis/Hemostasis 2003 ;9(1):1-17
Tobu,M.; Iqbal,O.; Messmore,H. L.; Ma,Q.; Hoppensteadt,D. A.; Fareed,J.Influence of different anticoagulant agents on fibrinopeptide a generation. Clinical & Applied Thrombosis/Hemostasis 2003 ;9(4):273-292
Hoppensteadt,D.; Walenga,J. M.; Fareed,J.; Bick,R. L.Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation Hematology - Oncology Clinics of North America 2003 ;17(1):313-341
Ma,Q.; Schultz,C.; Neville,B.; Jeske,W.; Hoppensteadt,D.; Cornelli,U.; Lee,J.; Lorens,S.; Hanin,I.; Fareed,J.Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates. Thrombosis research 2003 ;112(4):249-255
Iqbal,O.; Aziz,S.; Hoppensteadt,D. A.; Ahmad,S.; Walenga,J. M.; Bakhos,M.; Fareed,J.Emerging anticoagulant and thrombolytic drugs Expert opinion on emerging drugs 2001 ;6(1):111-135
Kanabrocki,E. L.; George,M.; Hermida,R. C.; Messmore,H. L.; Ryan,M. D.; Ayala,D. E.; Hoppensteadt,D. A.; Fareed,J.; Bremner,F. W.; Third,J. L.; Shirazi,P.; Nemchausky,B. A.Day-night variations in blood levels of nitric oxide, T-TFPI, and E-selectin. Clinical & Applied Thrombosis/Hemostasis 2001 ;7(4):339-345
Kanabrocki,E. L.; Third,J. L.; Ryan,M. D.; Nemchausky,B. A.; Shirazi,P.; Scheving,L. E.; McCormick,J. B.; Hermida,R. C.; Bremner,W. F.; Hoppensteadt,D. A.; Fareed,J.; Olwin,J. H.Circadian relationship of serum uric acid and nitric oxide. JAMA 2000 ;283(17):2240-2241